Harbour BioMed Announces Results of Phase Ib Clinical Trial of Porustobart in Combination with Toripalimab in Advanced High-Grade Neuroendocrine Neoplasms at AACR Annual Meeting

Porustobart in combination with toripalimab showed promising anti-tumor activity in advanced high-grade neuroendocrine neoplasms (NENs) The ORR and DCR were 38.5% and 69.2% in neuroendocrine carcinoma (NEC) patients The results showed great potential to develop porustobart as a…